Endeavor BioMedicines

What Endeavor BioMedicines does

Endeavor BioMedicines is a clinical-stage biotechnology company headquartered in San Diego, California, that develops precision medicines targeting the underlying biological drivers of fibrotic lung disease and oncology. Its lead asset, taladegib (ENV-101), is an orally bioavailable small-molecule inhibitor of the Hedgehog signaling pathway in Phase 2b development (WHISTLE-PF trial) for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company's stated thesis is disease modification rather than symptomatic slowing — the Phase 2a trial, published in The Lancet Respiratory Medicine, reported statistically significant improvement in percent predicted FVC (+1.9% vs -1.3% placebo), gains in total lung capacity, and reversal of quantitative fibrosis measures. Taladegib has received EMA Priority Medicines (PRIME) designation — the first investigational IPF therapy to do so — alongside Orphan Drug Designation from both the FDA and the European Commission.

The pipeline beyond taladegib includes two additional clinical-stage assets. ENV-501 is a next-generation HER3-targeted antibody-drug conjugate with an exatecan payload, in-licensed from Hummingbird Bioscience in October 2023 for up to $430 million in upfront and milestones plus royalties. ENV-501 is differentiated by an epitope that binds HER3 regardless of NRG1 ligand levels, addressing a key resistance mechanism in HER3-expressing tumors. ENV-201 is an orally available ULK1/2 autophagy inhibitor in development for KRAS/STK11-mutant cancers. Together the three programs span small-molecule pathway inhibition and biologic ADC modalities across two therapeutic verticals.

Endeavor BioMedicines is pre-revenue and has financed operations through approximately $295.5 million of venture capital across three rounds (Series A $62M in January 2021, Series B $101M in February 2022, Series C $132.5M in April 2024). The investor syndicate spans dedicated life-sciences firms (Omega Funds, Longitude Capital, Ally Bridge Group, Avidity Partners) and crossover/public-market investors (T. Rowe Price, Fidelity, Perceptive Advisors). Distribution of investigational products is exclusively via sponsored clinical trials; future revenue is expected from commercialization of approved assets or from out-licensing deals with larger pharmaceutical companies. The company was co-founded by John Hood, Ph.D. (previously founder of Impact Biomedicines, developer of fedratinib, acquired by Bristol Myers Squibb) and Miguel de los Rios, Ph.D.

Name

Endeavor BioMedicines

Legal name

Endeavor BioMedicines Inc.

Website

https://endeavorbiomedicines.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Endeavor BioMedicines is a clinical-stage biotechnology company developing precision medicines for fibrotic lung disease and oncology, with lead asset taladegib (ENV-101) in Phase 2b for idiopathic pulmonary fibrosis and additional programs in HER3-positive solid tumors and KRAS-driven cancers.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

akta.pro secondary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Pulmonary fibrosis therapeutics
• Antibody-drug conjugates
• Hedgehog pathway inhibitors
• Clinical-stage biopharmaceuticals
• HER3-targeted oncology

Headquarters

HQ city

Solana Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage company. Future revenue will be derived from commercialization of approved pharmaceutical products (ENV-101 for IPF, ENV-501 for solid tumors) through prescription sales, or through licensing/partnership agreements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Endeavor BioMedicines is a clinical-stage biotechnology company developing precision medicines targeting life-threatening diseases. Its lead investigational candidate is taladegib (ENV-101), an orally available small molecule inhibitor of the Hedgehog signaling pathway being developed for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company also develops ENV-501, a next-generation HER3-targeted antibody-drug conjugate (ADC) for HER3-positive solid tumors, and ENV-201, a ULK1/2 autophagy inhibitor for KRAS-driven cancers.

Product overview

Endeavor BioMedicines is a clinical-stage biotechnology company developing a pipeline of precision medicines targeting terminal diseases. The company's portfolio consists of three investigational drug candidates: (1) Taladegib (ENV-101), a Hedgehog signaling pathway inhibitor for fibrotic lung diseases including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis; (2) ENV-501, a HER3-targeted antibody-drug conjugate for HER3-positive solid tumors; and (3) ENV-201, a ULK1/2 inhibitor for KRAS-driven cancers. The company is focused on developing disease-modifying therapies that address the underlying causes of these conditions rather than just slowing disease progression.

Differentiator

Problem solved

Functional benefit

Products and services

• Taladegib (ENV-101) Orally available small molecule inhibitor of the Hedgehog signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It binds to and inhibits the PTCH1 receptor, eliminating myofibroblasts that cause fibrosis, with the potential to reverse lung fibrosis and improve lung function. Phase 2a data showed statistically significant improvement in percent predicted FVC (+1.9% vs -1.3% placebo) and reversal of key measures of lung fibrosis. Received EMA PRIME designation and FDA and EC Orphan Drug Designation.
• ENV-501 Next-generation HER3-targeted antibody-drug conjugate (ADC) with an exatecan payload for the treatment of HER3-positive solid tumors. Engineered to bind a novel HER3 epitope such that binding is unaffected by NRG1 ligand levels, allowing binding to HER3-expressing tumors even in high ligand contexts. Designed to minimize off-target toxicity with enhanced tumor delivery.
• ENV-201 Orally available small molecule inhibitor of ULK1/2, a critical enzyme in autophagy, for the treatment of KRAS-driven cancers. Targets tumors with KRAS and STK11 mutations that are highly dependent on the autophagy recycling pathway.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Hummingbird BiosciencecoreStrategic or Co-development Partner · 19 October 2023Endeavor acquired exclusive worldwide rights to HMBD-501 (now ENV-501), a next-generation HER3-targeted ADC with exatecan payload. Hummingbird Bio's proprietary antibody discovery and engineering platform enabled the differentiated ADC. Hummingbird eligible for upfront and milestone payments up to $430 million plus royalties.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/EndeavorBioMed
• LinkedInlinkedin.com/company/endeavor-biomedicines

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds3 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endeavor BioMedicines